Full video transcriptClick to expand
Auto-generated transcript of @lesters_labs's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00The
- 0:49Yet, the first change in the past is a good way to get together to be able to get there.
- 0:54That means the first change in the over-range, this will be the next one.
- 1:00It's next. It's the first change in the last level.
- 1:04And it's not the second. The second is the first change in the last level.
- 1:08I think it's the third change in the last period.
- 1:14The fifth change in the fourth level is the second failure.
- 1:48I have no idea what it is, but I am a fan of it.
- 1:51I'm a fan of it from the famous Gama YouTube,
- 1:53and I'm a super fan of it.
- 1:56I'm a super fan of it.
- 1:58I'm a super fan of it.
- 1:59I'm a super fan of it from the Gama YouTube channel.
@lesters_labs's thick blood claims on TRT, fact-checked
Quick answer
TRT increases hematocrit in 20-30% of men by stimulating erythropoietin production. Established management includes therapeutic phlebotomy, dose reduction, or formulation changes. Hepcidin modulation through other hormones remains unproven in this population.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @lesters_labs's thick blood claims on TRT, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@lesters_labs's thick blood claims on TRT, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@lesters_labs's thick blood claims on TRT, fact-checked" from Lester Buhrmann. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: TRT increases hematocrit in 20-30% of men by stimulating erythropoietin production.
The reason this review is not generic is the source wording and the canonical claim label "trt zu dickes blut h matokrit senken auf trt quellen hepcidin." In this clip, the useful excerpt is: "The Yet, the first change in the past is a good way to get together to be able to get there." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
TRT increases hematocrit in 20-30% of men by stimulating erythropoietin production.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- TRT increases hematocrit in 20-30% of men by stimulating erythropoietin production. Established management includes therapeutic phlebotomy, dose reduction, or formulation changes. Hepcidin modulation through other hormones remains unproven in this population.
- TRT raises hematocrit in 20-30% of men by 2-5 percentage points on average
- Therapeutic blood donation reduces hematocrit by 3-6 percentage points within weeks
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- TRT raises hematocrit in 20-30% of men by 2-5 percentage points on average
- Therapeutic blood donation reduces hematocrit by 3-6 percentage points within weeks
- Progesterone does increase hepcidin in some studies, but mainly in postmenopausal women
- Estrogen's effects on hepcidin are inconsistent across different studies and populations
- No studies have tested hepcidin manipulation specifically for TRT-related polycythemia
- Dose reduction and formulation changes are proven alternatives to phlebotomy
- Most men tolerate hematocrit levels up to 52-54% without health problems
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this video actually claim?
Lester Buhrmann claims testosterone replacement therapy (TRT) causes thick blood by raising hematocrit levels, and suggests hormones like progesterone and estrogen can fix this by influencing hepcidin, a protein that regulates iron absorption. He's basically arguing you can manipulate your blood thickness through hormonal tweaks instead of the standard approaches doctors typically use.
The video targets bodybuilders and biohackers on TRT who worry about elevated red blood cell counts. It's presented as a science-backed solution with multiple study citations.
Does the science support hepcidin manipulation?
The hepcidin connection is real but oversimplified. Hepcidin does regulate iron absorption and can influence red blood cell production, as shown in Ganz & Nemeth's 2015 review in Blood. Higher hepcidin levels reduce iron availability, which can theoretically lower hematocrit over time.
However, the hormone-hepcidin relationships Buhrmann cites are mostly from observational studies or animal research. The 2015 study by Lehtihet et al. (PMID: 26657863) did find progesterone increased hepcidin in postmenopausal women, but that's quite different from young men on TRT.
The estrogen studies he references show mixed results. Some found estrogen increased hepcidin, others showed decreases depending on timing and dose.
What's missing from this approach?
Buhrmann ignores the most proven methods for managing TRT-related polycythemia. Regular blood donation reduces hematocrit by 3-6 percentage points within weeks, according to multiple studies including work by Samiee-Rad et al. in 2019.
He also skips over dose optimization. Many men can lower their hematocrit simply by reducing testosterone dose or switching from injections to gels, which create less erythropoietin stimulation.
The video doesn't mention that most healthy men tolerate hematocrit levels up to 52-54% without problems. The obsession with driving it lower might be unnecessary for many people.
What should you actually know?
TRT does raise hematocrit in about 20-30% of men, typically by 2-5 percentage points above baseline. This happens because testosterone stimulates erythropoietin production in the kidneys, leading to more red blood cell creation.
If your hematocrit climbs above 52-54%, proven solutions include therapeutic blood donation every 8-12 weeks, dose reduction, or switching formulations. These approaches work reliably and quickly.
The hepcidin manipulation strategy might work in theory, but it's unproven in TRT patients. You'd be experimenting with additional hormones to solve a problem that has established solutions. That seems unnecessarily complicated for most people.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Lester Buhrmann · Instagram creator
33.5K views on this video
Zu dickes Blut - Hämatokrit senken auf TRT Quellen: Hepcidin und Hämatokrit https://doi.org/10.3389/fphys.2019.01294 Progesteron und Hepcidin PMID: 26657863 Hepcidin und Progesteron bei Frauen https:/
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about trt raises hematocrit in 20-30% of men by 2-5 percentage?
TRT raises hematocrit in 20-30% of men by 2-5 percentage points on average
What does the video say about therapeutic blood donation reduces hematocrit by 3-6 percentage points within?
Therapeutic blood donation reduces hematocrit by 3-6 percentage points within weeks
What does the video say about progesterone does increase hepcidin in some studies,?
Progesterone does increase hepcidin in some studies, but mainly in postmenopausal women
What does the video say about estrogen's effects on hepcidin?
Estrogen's effects on hepcidin are inconsistent across different studies and populations
What does the video say about no studies have tested hepcidin manipulation specifically for trt-related polycythemia?
No studies have tested hepcidin manipulation specifically for TRT-related polycythemia
Dose reduction and formulation changes are proven alternatives to phlebotomy?
Dose reduction and formulation changes are proven alternatives to phlebotomy
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Lester Buhrmann, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.